MD-50

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MD-50 (MD-50).

How it works

Iodinated radiographic contrast agent that attenuates X-rays due to its high iodine content, allowing visualization of vascular structures and organs during imaging. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.

What the body does with it

Metabolism	Not metabolized. Eliminated unchanged by glomerular filtration. No hepatic metabolism.
Excretion	Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Half-life	Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Protein binding	Low protein binding; approximately 2-5% bound to serum albumin. This low binding minimizes protein displacement interactions and contributes to rapid renal clearance.
Volume of Distribution	Volume of distribution is 0.2-0.3 L/kg, indicating distribution primarily in extracellular fluid. This low Vd is consistent with water-soluble contrast agents that do not cross cell membranes and are confined to the vascular and interstitial spaces.
Bioavailability	Intravenous: 100% bioavailability by definition. Oral: negligible (<1%) due to poor gastrointestinal absorption and extensive degradation. Intra-arterial: equivalent to IV. Intrathecal: absorbed systemically but bioavailability not relevant for intended use; local effect.
Onset of Action	Intravenous: immediate onset with visible contrast enhancement within seconds; Intra-arterial: immediate onset at site of injection; Oral/enteric routes not applicable; Intraspinal: immediate but CSF opacification occurs within 5 minutes.
Duration of Action	Intravenous: contrast enhancement lasts 5-15 minutes for vascular phases, with parenchymal enhancement lasting up to 30-60 minutes. The drug is rapidly redistributed and eliminated, limiting contamination of subsequent images. Clinical effect is diagnostic visibility during imaging.

Classification & Brands

Dosing & administration

300 mg intravenously every 12 hours.

Dosage form	INJECTABLE
Renal impairment	GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: 300 mg every 24 hours; GFR <15 mL/min: 300 mg every 48 hours.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: not recommended.
Pediatric use	For patients 1 month to 18 years: 5 mg/kg intravenously every 12 hours (max 300 mg per dose).
Geriatric use	No specific dose adjustment; monitor renal function as age-related decline may necessitate use of renal adjustment criteria.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MD-50 (MD-50).

Breastfeeding	Iodinated contrast is excreted into breast milk; M/P ratio ~0.01. Amount absorbed by infant is negligible (<0.01% of maternal dose). No adverse effects reported. Cautious recommendation: continue breastfeeding; optional pump and discard for 12-24 hours.
Teratogenic Risk	FDA Category C. First trimester: Iodinated contrast crosses placenta; theoretical risk of fetal thyroid suppression, but human data limited. Second/third trimester: No teratogenic signals; use only if clearly indicated. Neonatal hypothyroidism risk if given near term.

Warnings & precautions

■ FDA Black Box Warning

Risk of serious hypersensitivity reactions, including anaphylaxis and death. Fatal reactions have occurred in patients with known hypersensitivity to iodinated contrast agents. Nonionic contrast agents like MD-50 carry a lower risk but still require caution.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Absolute: Known hypersensitivity to MD-50 or any component","Absolute: Previous life-threatening reaction to iodinated contrast agents","Relative: Acute or chronic severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dialysis is available","Relative: Hyperthyroidism or thyroid autonomy"]

Clinical Precautions

Precautions

["Risk of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing renal impairment, diabetes, or dehydration","Severe hypersensitivity reactions (anaphylaxis, bronchospasm, angioedema) requiring emergency treatment","Thyroid storm in patients with hyperthyroidism or thyroid autonomy","Extravasation risk: local tissue injury and necrosis","Sickle cell disease: risk of sickling in patients with homozygous sickle cell disease","Pheochromocytoma: hypertensive crisis risk"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MD-50

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MD-50 (MD-50).

How it works

What the body does with it

Metabolism	Not metabolized. Eliminated unchanged by glomerular filtration. No hepatic metabolism.
Excretion	Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Half-life	Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Protein binding	Low protein binding; approximately 2-5% bound to serum albumin. This low binding minimizes protein displacement interactions and contributes to rapid renal clearance.
Volume of Distribution	Volume of distribution is 0.2-0.3 L/kg, indicating distribution primarily in extracellular fluid. This low Vd is consistent with water-soluble contrast agents that do not cross cell membranes and are confined to the vascular and interstitial spaces.
Bioavailability	Intravenous: 100% bioavailability by definition. Oral: negligible (<1%) due to poor gastrointestinal absorption and extensive degradation. Intra-arterial: equivalent to IV. Intrathecal: absorbed systemically but bioavailability not relevant for intended use; local effect.
Onset of Action	Intravenous: immediate onset with visible contrast enhancement within seconds; Intra-arterial: immediate onset at site of injection; Oral/enteric routes not applicable; Intraspinal: immediate but CSF opacification occurs within 5 minutes.
Duration of Action	Intravenous: contrast enhancement lasts 5-15 minutes for vascular phases, with parenchymal enhancement lasting up to 30-60 minutes. The drug is rapidly redistributed and eliminated, limiting contamination of subsequent images. Clinical effect is diagnostic visibility during imaging.

Classification & Brands

Dosing & administration

300 mg intravenously every 12 hours.

Dosage form	INJECTABLE
Renal impairment	GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: 300 mg every 24 hours; GFR <15 mL/min: 300 mg every 48 hours.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: not recommended.
Pediatric use	For patients 1 month to 18 years: 5 mg/kg intravenously every 12 hours (max 300 mg per dose).
Geriatric use	No specific dose adjustment; monitor renal function as age-related decline may necessitate use of renal adjustment criteria.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MD-50 (MD-50).

Breastfeeding	Iodinated contrast is excreted into breast milk; M/P ratio ~0.01. Amount absorbed by infant is negligible (<0.01% of maternal dose). No adverse effects reported. Cautious recommendation: continue breastfeeding; optional pump and discard for 12-24 hours.
Teratogenic Risk	FDA Category C. First trimester: Iodinated contrast crosses placenta; theoretical risk of fetal thyroid suppression, but human data limited. Second/third trimester: No teratogenic signals; use only if clearly indicated. Neonatal hypothyroidism risk if given near term.